Baidu
map

Brit J Cancer:质子泵抑制剂和组胺-2受体拮抗剂与胃癌风险

2020-05-05 MedSci原创 MedSci原创

该研究的结果中几乎没有一致的证据表明服用PPI会增加胃癌风险。

研究表明,质子泵抑制剂(PPI)和组胺2受体拮抗剂的使用者胃癌风险增加,因此,胃酸抑制的安全性受到质疑。近日,肿瘤领域权威杂志British Journal of Cancer上发表了一篇研究文章,研究人员在苏格兰基层医疗临床信息学部门(PCCIU)数据库中进行了一项病例对照研究,并在UK生物库中进行了一项队列研究。

在PCCIU中,研究人员将五名对照者与一名1999-2011年期间诊断的病例相匹配,并根据GP记录确定药物使用情况。研究人员使用条件Logsitic回归计算比值比(OR)和95%置信区间(CI)。在UK生物库中,受试者服用药物情况是在2006-2010年期间进入队列时自我报告的,研究人员从癌症登记处确定了受试者胃癌情况,直到2014年为止。研究人员使用Cox回归计算了风险比(HR)。

PCCIU纳入了1119例病例和5394例对照者。UK生物库中有471779名参与者,其中包含了250例病例。使用1年滞后时,PPI服用者在PCCIU和UK生物库中有较高的胃癌风险(校正后OR=1.49,95%CI为1.24-1.80;校正后HR=1.28,95%CI为0.86-1.90),但是当使用2年滞后时,这些关联有所减弱(校正OR=1.13,95%CI为0.91-1.40;校正HR=1.15,95%CI为0.73-1.82)。

总体而言,该研究的结果中几乎没有一致的证据表明服用PPI会增加胃癌风险。

原始出处:

Peipei Liu,et al.Use of proton pump inhibitors and histamine-2 receptor antagonists and risk of gastric cancer in two population-based studies.British Journal of Cancer.2020.https://www.nature.com/articles/s41416-020-0860-4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1852357, encodeId=491b185235e4e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 30 15:56:18 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061933, encodeId=b910206193341, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Sep 08 12:56:18 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742160, encodeId=33b91e4216099, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Tue Mar 30 20:56:18 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667371, encodeId=6528166e37175, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Fri Mar 05 20:56:18 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804867, encodeId=9373180486ef6, content=<a href='/topic/show?id=ba41e7735ab' target=_blank style='color:#2F92EE;'>#组胺-2受体拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77735, encryptionId=ba41e7735ab, topicName=组胺-2受体拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Thu Sep 24 21:56:18 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511759, encodeId=bcb61511e597c, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu May 07 03:56:18 CST 2020, time=2020-05-07, status=1, ipAttribution=)]
    2020-11-30 jklm09
  2. [GetPortalCommentsPageByObjectIdResponse(id=1852357, encodeId=491b185235e4e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 30 15:56:18 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061933, encodeId=b910206193341, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Sep 08 12:56:18 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742160, encodeId=33b91e4216099, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Tue Mar 30 20:56:18 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667371, encodeId=6528166e37175, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Fri Mar 05 20:56:18 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804867, encodeId=9373180486ef6, content=<a href='/topic/show?id=ba41e7735ab' target=_blank style='color:#2F92EE;'>#组胺-2受体拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77735, encryptionId=ba41e7735ab, topicName=组胺-2受体拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Thu Sep 24 21:56:18 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511759, encodeId=bcb61511e597c, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu May 07 03:56:18 CST 2020, time=2020-05-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1852357, encodeId=491b185235e4e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 30 15:56:18 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061933, encodeId=b910206193341, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Sep 08 12:56:18 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742160, encodeId=33b91e4216099, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Tue Mar 30 20:56:18 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667371, encodeId=6528166e37175, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Fri Mar 05 20:56:18 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804867, encodeId=9373180486ef6, content=<a href='/topic/show?id=ba41e7735ab' target=_blank style='color:#2F92EE;'>#组胺-2受体拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77735, encryptionId=ba41e7735ab, topicName=组胺-2受体拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Thu Sep 24 21:56:18 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511759, encodeId=bcb61511e597c, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu May 07 03:56:18 CST 2020, time=2020-05-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1852357, encodeId=491b185235e4e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 30 15:56:18 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061933, encodeId=b910206193341, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Sep 08 12:56:18 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742160, encodeId=33b91e4216099, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Tue Mar 30 20:56:18 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667371, encodeId=6528166e37175, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Fri Mar 05 20:56:18 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804867, encodeId=9373180486ef6, content=<a href='/topic/show?id=ba41e7735ab' target=_blank style='color:#2F92EE;'>#组胺-2受体拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77735, encryptionId=ba41e7735ab, topicName=组胺-2受体拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Thu Sep 24 21:56:18 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511759, encodeId=bcb61511e597c, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu May 07 03:56:18 CST 2020, time=2020-05-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1852357, encodeId=491b185235e4e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 30 15:56:18 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061933, encodeId=b910206193341, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Sep 08 12:56:18 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742160, encodeId=33b91e4216099, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Tue Mar 30 20:56:18 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667371, encodeId=6528166e37175, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Fri Mar 05 20:56:18 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804867, encodeId=9373180486ef6, content=<a href='/topic/show?id=ba41e7735ab' target=_blank style='color:#2F92EE;'>#组胺-2受体拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77735, encryptionId=ba41e7735ab, topicName=组胺-2受体拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Thu Sep 24 21:56:18 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511759, encodeId=bcb61511e597c, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu May 07 03:56:18 CST 2020, time=2020-05-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1852357, encodeId=491b185235e4e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54918, encryptionId=f0a254918f0, topicName=抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=44a360, createdName=jklm09, createdTime=Mon Nov 30 15:56:18 CST 2020, time=2020-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2061933, encodeId=b910206193341, content=<a href='/topic/show?id=e6e1e15509f' target=_blank style='color:#2F92EE;'>#癌风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71550, encryptionId=e6e1e15509f, topicName=癌风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Sep 08 12:56:18 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742160, encodeId=33b91e4216099, content=<a href='/topic/show?id=a830e7734a0' target=_blank style='color:#2F92EE;'>#组胺#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77734, encryptionId=a830e7734a0, topicName=组胺)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6235043235, createdName=bluefate133, createdTime=Tue Mar 30 20:56:18 CST 2021, time=2021-03-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1667371, encodeId=6528166e37175, content=<a href='/topic/show?id=03ab923565b' target=_blank style='color:#2F92EE;'>#质子泵#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92356, encryptionId=03ab923565b, topicName=质子泵)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=761326143554, createdName=shenxlcyp, createdTime=Fri Mar 05 20:56:18 CST 2021, time=2021-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1804867, encodeId=9373180486ef6, content=<a href='/topic/show?id=ba41e7735ab' target=_blank style='color:#2F92EE;'>#组胺-2受体拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77735, encryptionId=ba41e7735ab, topicName=组胺-2受体拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c25323, createdName=jambiya, createdTime=Thu Sep 24 21:56:18 CST 2020, time=2020-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511759, encodeId=bcb61511e597c, content=<a href='/topic/show?id=90d75628960' target=_blank style='color:#2F92EE;'>#拮抗剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56289, encryptionId=90d75628960, topicName=拮抗剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474c10379153, createdName=ms5236388012055669, createdTime=Thu May 07 03:56:18 CST 2020, time=2020-05-07, status=1, ipAttribution=)]

相关资讯

J Gastroenterology:早期胃癌非根治性内镜切除术后淋巴结转移的患病率和危险因素分析

由于早期胃癌患者的淋巴结转移率(LNM)相对较低,因此对于早期胃癌(EGC)在内镜切除术(ER)后所有非治愈性切除术的患者进行额外的手术可能产生过度医疗的现象。

Cell Death Dis:间充质干细胞lncRNA HCP5引发脂肪酸氧化反应促进胃癌干细胞特性及耐药性

长期以来,胃癌(GC)一直是肿瘤相关死亡的首要原因,尽管手术导向的综合疗法被认为是晚期GC患者的首选,但患者术后的5年生存率仅有20%-50%。除手术外,化疗也是GC患者主要的临床治疗手段。不幸的是,

Gastric Cancer:胃癌的代谢产物可以预测腹膜复发

代谢组学可用于分析癌症进展所需的营养状况,本项研究评估了胃癌(GC)组织的代谢组学概况,以阐明代谢与癌症复发之间的关联。

Gastric Cancer :CDX2,GPA33和LI-钙黏着蛋白表达水平与胃癌患者良好预后有关

胃癌是第五大最常见的癌症,也是全球癌症死亡率的第三大原因。CDX2是在胃癌中具有预后价值的肠道分化标志物,同时也会转录调节糖蛋白A33(GPA33)和肝肠钙粘蛋白(LI-cadherin)的表达。

Gastric Cancer:单纯手术足以治疗具有广泛淋巴结转移的T1胃癌

单独手术是否足以治疗T1N2M0(IIA期),T1N3a / bM0(IIB / IIIB期)和T3N0M0(IIA期)胃癌的患者仍不清楚。本项研究旨在探究这一可能性。

Cancer Res:胃癌免疫治疗新思路

2020年3月10日 ,上海交通大学生物医学工程学院高维强、马斌课题组在美国癌症研究协会(AACR) 的国际知名期刊 Cancer Research上在线发表研究成果&ldquo

Baidu
map
Baidu
map
Baidu
map